Efavirenz Outperforms Boosted Atazanavir among Treatment-Naive HIV-1-Infected Persons in Routine Clinical Care
| Autor: | Toshibumi Taniguchi MD, Jessica R. Grubb MD, Diana Nurutdinova MD, Nur F. Önen MD, Enbal Shacham PhD, Michael Donovan BS, Edgar Turner Overton MD |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: | |
| Zdroj: | Journal of the International Association of Providers of AIDS Care, Vol 12 (2013) |
| Druh dokumentu: | article |
| ISSN: | 2325-9574 2325-9582 15451097 |
| DOI: | 10.1177/1545109712467057 |
| Popis: | Background: Effectiveness of antiretroviral therapy (ART) in a routine clinical care may result different from the clinical trials. We assessed the virologic outcomes in treatment-naive persons who received either efavirenz (EFV) or atazanavir/ritonavir (ATV/r) with a backbone of tenofovir/emtricitabine (TDF/FTC) as their combination ART (cART). Methods: This was a retrospective cohort study conducted at the Washington University HIV Outpatient Clinic from January 2004 to June 2009. Predictors of virologic suppression (HIV RNA level |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|